Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 6 | 2023 | 235 | 1.770 |
Why?
|
| Lung Transplantation | 4 | 2023 | 175 | 1.730 |
Why?
|
| Pulmonary Fibrosis | 8 | 2023 | 123 | 1.540 |
Why?
|
| Alveolar Epithelial Cells | 4 | 2020 | 18 | 1.070 |
Why?
|
| DNA, Mitochondrial | 6 | 2021 | 183 | 1.060 |
Why?
|
| Sirtuin 3 | 3 | 2021 | 29 | 0.830 |
Why?
|
| Tissue and Organ Procurement | 2 | 2023 | 311 | 0.810 |
Why?
|
| Myositis | 1 | 2020 | 17 | 0.730 |
Why?
|
| Scleroderma, Systemic | 1 | 2018 | 43 | 0.650 |
Why?
|
| Apoptosis | 4 | 2020 | 1683 | 0.580 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 3 | 2023 | 165 | 0.550 |
Why?
|
| Hypertension, Pulmonary | 1 | 2018 | 346 | 0.500 |
Why?
|
| Patient Selection | 1 | 2018 | 686 | 0.500 |
Why?
|
| DNA Damage | 5 | 2021 | 366 | 0.500 |
Why?
|
| Asbestos | 5 | 2021 | 22 | 0.480 |
Why?
|
| Mitochondria | 5 | 2021 | 535 | 0.460 |
Why?
|
| Waiting Lists | 2 | 2023 | 175 | 0.390 |
Why?
|
| Oxidants | 2 | 2017 | 86 | 0.290 |
Why?
|
| Transplant Recipients | 2 | 2023 | 122 | 0.240 |
Why?
|
| Bleomycin | 3 | 2020 | 98 | 0.230 |
Why?
|
| Emphysema | 1 | 2023 | 22 | 0.230 |
Why?
|
| Pulmonary Emphysema | 1 | 2023 | 30 | 0.230 |
Why?
|
| Monocytes | 2 | 2021 | 214 | 0.220 |
Why?
|
| Policy | 1 | 2023 | 34 | 0.220 |
Why?
|
| DNA Glycosylases | 2 | 2020 | 24 | 0.220 |
Why?
|
| Frailty | 1 | 2023 | 58 | 0.210 |
Why?
|
| Rheumatoid Factor | 1 | 2021 | 24 | 0.210 |
Why?
|
| Mediastinal Diseases | 1 | 2021 | 21 | 0.210 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 17 | 0.210 |
Why?
|
| Registries | 2 | 2021 | 703 | 0.200 |
Why?
|
| Inhalation Exposure | 1 | 2021 | 28 | 0.190 |
Why?
|
| Occupational Health | 1 | 2021 | 32 | 0.190 |
Why?
|
| Asbestosis | 1 | 2020 | 5 | 0.190 |
Why?
|
| Catalase | 2 | 2017 | 48 | 0.180 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2020 | 18 | 0.180 |
Why?
|
| Occupational Exposure | 1 | 2021 | 80 | 0.180 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2021 | 166 | 0.180 |
Why?
|
| Tissue Donors | 1 | 2023 | 463 | 0.180 |
Why?
|
| Gene Expression | 2 | 2021 | 1284 | 0.170 |
Why?
|
| Humans | 15 | 2023 | 86645 | 0.170 |
Why?
|
| Protein Kinases | 1 | 2020 | 209 | 0.170 |
Why?
|
| Lung | 2 | 2023 | 1170 | 0.150 |
Why?
|
| Glucuronidase | 1 | 2017 | 20 | 0.150 |
Why?
|
| A549 Cells | 1 | 2017 | 39 | 0.150 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 71 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 114 | 0.140 |
Why?
|
| Mice | 6 | 2021 | 11352 | 0.140 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 123 | 0.130 |
Why?
|
| Aging | 2 | 2017 | 691 | 0.130 |
Why?
|
| Epithelial Cells | 1 | 2016 | 669 | 0.110 |
Why?
|
| Mice, Knockout | 1 | 2017 | 1924 | 0.110 |
Why?
|
| Animals | 7 | 2021 | 26582 | 0.100 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 1540 | 0.100 |
Why?
|
| Oxidative Stress | 3 | 2021 | 447 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2023 | 4213 | 0.090 |
Why?
|
| Male | 8 | 2023 | 40967 | 0.080 |
Why?
|
| Salicylates | 2 | 2017 | 25 | 0.070 |
Why?
|
| Organometallic Compounds | 2 | 2017 | 132 | 0.070 |
Why?
|
| Female | 7 | 2023 | 44534 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 1920 | 0.070 |
Why?
|
| Biomarkers | 2 | 2021 | 1718 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2023 | 8491 | 0.060 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 25 | 0.060 |
Why?
|
| Reactive Oxygen Species | 2 | 2016 | 480 | 0.060 |
Why?
|
| Australasia | 1 | 2023 | 4 | 0.060 |
Why?
|
| Time Factors | 2 | 2021 | 5210 | 0.050 |
Why?
|
| North America | 1 | 2023 | 180 | 0.050 |
Why?
|
| Canada | 1 | 2023 | 204 | 0.050 |
Why?
|
| Telomere | 1 | 2023 | 108 | 0.050 |
Why?
|
| Leukocytes | 1 | 2023 | 202 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 2232 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 137 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 859 | 0.050 |
Why?
|
| Titanium | 1 | 2020 | 20 | 0.050 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2020 | 9 | 0.050 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 72 | 0.050 |
Why?
|
| Macrophages, Alveolar | 1 | 2020 | 55 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2020 | 158 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 203 | 0.040 |
Why?
|
| United States | 2 | 2021 | 6674 | 0.040 |
Why?
|
| Middle Aged | 3 | 2021 | 25028 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 547 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2020 | 3241 | 0.040 |
Why?
|
| Survival Rate | 1 | 2021 | 1863 | 0.040 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2017 | 16 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2017 | 44 | 0.040 |
Why?
|
| Protective Agents | 1 | 2017 | 33 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2016 | 3 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 1531 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1673 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1753 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2379 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 1239 | 0.040 |
Why?
|
| Macrophages | 1 | 2020 | 554 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2016 | 159 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2016 | 188 | 0.040 |
Why?
|
| Transgenes | 1 | 2016 | 180 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2023 | 2767 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 179 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 322 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2016 | 144 | 0.030 |
Why?
|
| Aged | 2 | 2023 | 18415 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 2501 | 0.030 |
Why?
|
| Collagen | 1 | 2016 | 269 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2705 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1585 | 0.030 |
Why?
|
| Guanine | 1 | 2015 | 208 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 3640 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2262 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 3680 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 3092 | 0.030 |
Why?
|
| DNA Repair | 1 | 2015 | 356 | 0.030 |
Why?
|
| Peptides | 1 | 2016 | 639 | 0.030 |
Why?
|
| Adult | 2 | 2023 | 25648 | 0.030 |
Why?
|
| Cell Line | 1 | 2017 | 2468 | 0.030 |
Why?
|
| Child | 1 | 2023 | 6928 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2017 | 1981 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 5417 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2601 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 2262 | 0.010 |
Why?
|